Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00119730 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00119730 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT00119730, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
* The purpose of this study is to find out whether combining a short course of chemotherapy (Fludarabine, Mitoxantrone and Rituximab) followed by Zevalin will be effective in treating relapsed mantle cell lymphoma. * The secondary purposes of the study are to determine the safety and to evaluate whether there is additional benefit from Zevalin therapy following the chemotherapy.
Interventions
- DRUG Fludarabine
- DRUG Rituximab
- DRUG Mitoxantrone
- DRUG Zevalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00119730
The ClinicalTrials.gov registry entry for NCT00119730 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine is the first listed.
NCT00119730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00119730 about?
NCT00119730 is a clinical study titled "Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma". * The purpose of this study is to find out whether combining a short course of chemotherapy (Fludarabine, Mitoxantrone and Rituximab) followed by Zevalin will be effective in treating relapsed mantle cell lymphoma. * The secondary purposes of the study are to determine the safety and to evaluate whe...
What is the current status of trial NCT00119730?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00119730?
The interventions under investigation include: Fludarabine (DRUG), Rituximab (DRUG), Mitoxantrone (DRUG), Zevalin (DRUG).
Who is sponsoring clinical trial NCT00119730?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.